Mouse pre-microRNA Expression Construct mir-224
- Known as:
- Mouse pre-microRNA Expression Construct mir-224
- Catalog number:
- mmir-224-pa-1
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Sbi systeme bioscience
- Gene target:
- Mouse pre-microRNA Expression Construct mir-224
Related genes to: Mouse pre-microRNA Expression Construct mir-224
- Gene:
- MIR224 NIH gene
- Name:
- microRNA 224
- Previous symbol:
- MIRN224
- Synonyms:
- hsa-mir-224
- Chromosome:
- Xq28
- Locus Type:
- RNA, micro
- Date approved:
- 2004-04-23
- Date modifiied:
- 2019-01-18
Related products to: Mouse pre-microRNA Expression Construct mir-224
Related articles to: Mouse pre-microRNA Expression Construct mir-224
- MicroRNAs (miRNAs) are increasingly recognized as central regulators of gene expression, cellular adaptation, and disease progression. This is fundamentally reshaping current understanding of disease molecular pathogenesis and therapeutic intervention. Beyond their established roles in development and metabolism, miRNAs actively participate in oncogenesis, metabolic dysfunction, inflammation, and redox homeostasis. Emerging evidence shows that phytochemicals can modulate miRNA-mediated regulatory networks by influencing miRNA biogenesis, expression, stability, and functional activity through transcriptional, epigenetic, and post-transcriptional mechanisms. Among these pathways, the thioredoxin-interacting protein (TXNIP) axis has attracted considerable attention because of its critical involvement in oxidative stress, inflammation, metabolic reprogramming, apoptosis, and cancer-associated signalling. For instance, dysregulated TXNIP expression is strongly associated with metabolic dysfunction-associated fatty liver disease (MAFLD), diabetes, cardiovascular diseases, neurodegenerative disorders, and multiple cancers, making it an attractive therapeutic target. This narrative review discussed emerging trends on phytochemical-mediated regulation of TXNIP-associated miRNAs, including miR-148b, miR-33a/b, miR-17-5p, miR-224, and miR-20a. Particular emphasis was placed on the conserved miRNA seed region as the principal determinant of target recognition, while discussing the emerging hypothesis that phytochemicals may allosterically modulate structurally accessible RNA motifs to influence miRNA conformation, stability, RNA-induced silencing complex loading, and target accessibility without disrupting canonical Watson-Crick base pairing. We further discussed molecular docking, RNA-specific molecular dynamics simulations, and complementary structural validation approaches as emerging tools for investigating RNA-ligand interactions. Therefore, this review has provided a mechanistic and translational framework integrating RNA biology, redox signalling, and precision medicine to guide future development of RNA-targeted phytochemical therapeutics for cancer, metabolic disorders, and other chronic diseases. - Source: PubMed
Publication date: 2026/08/25
Agu Peter ChineduAja Patrick MaduabuchiOfor Cecilia OgechiRoss KehindeLu Jun - Pulmonary arterial hypertension (PAH) is a progressive pulmonary vascular disease that leads to right heart failure and ultimately death. Therapeutic options targeting the underlying mechanisms of the disease are urgently needed. MicroRNAs (miRs) have emerged as critical regulators of cardiovascular homeostasis and disease. Here, we identified microRNA-224-5p (miR-224) as a regulator of pulmonary vascular remodeling and delineate its mechanism of action in PAH. miR-224 expression was increased in the lungs of patients with PAH and across multiple experimental models of pulmonary hypertension, including mouse, rat, and pig models, as well as in pulmonary arterial smooth muscle cells (PASMCs) isolated from patients with PAH. In vitro, miR-224 overexpression was sufficient to induce PASMC proliferation. In vivo, adeno-associated virus 1 (AAV1)-mediated overexpression of miR-224 exacerbated PAH in mice, whereas intratracheal delivery of aerosolized AAV1-ToughDecoy-miR-224 or a chemically modified antisense oligonucleotide targeting miR-224 (LNA-224) attenuated disease severity in Sugen/Hypoxia (Su/Hx) and monocrotaline models in both mice and rats. Moreover, SMC-specific inhibition of miR-224 via an AAV1 vector expressing ToughDecoy-miR-224 reversed pulmonary vascular remodeling and improved right ventricular function in the Su/Hx mouse model. Mechanistically, miR-224 targeted multiple components of the bone morphogenetic protein (BMP)/transforming growth factor-β (TGFβ) signaling pathway, leading to suppressed BMP/SMAD signaling and enhanced TGFβ-associated responses. Inhibition of miR-224 restored the balance between growth-inhibitory BMP signaling and growth-promoting TGFβ signaling in PASMCs. Collectively, these findings identify miR-224 as a regulator of pulmonary vascular remodeling and highlight miR-224 inhibition as a promising therapeutic strategy for PAH. - Source: PubMed
Publication date: 2026/09/02
Bikou OlympiaHalouani AymenSun YifeiBisserier MalikEisenacher ClemensAntar Samar AAvramopoulos PetrosSantos-Gallego Carlos GSwarts CatherineKohlbrenner ErikIshikawa KiyotakeHumbert MarcHajjar Roger JLax AntonioEngelhardt StefanWalsh Martin JBonnet SebastienHadri LahouariaSassi Yassine - Hepatocellular carcinoma (HCC) remains a major global health burden, characterized by late diagnosis, limited therapeutic options, and high mortality rates. Conventional diagnostic tools such as serum α-fetoprotein testing and imaging lack sufficient sensitivity for early detection. In recent years, liquid biopsy has emerged as a minimally invasive approach that enables real-time molecular profiling of tumors through the analysis of circulating biomarkers such as nucleic acids, proteins, and extracellular vesicles. Recent advances have underscored exosomes-nano-sized extracellular vesicles (EVs) secreted by nearly all cell types-as pivotal mediators of intercellular communication and dynamic carriers of tumor-derived molecular information, offering exciting prospects for early cancer detection and personalized therapy. In HCC, EV microRNAs (miRNAs) participate in multiple oncogenic processes, including proliferation, angiogenesis, epithelial-mesenchymal transition, and immune modulation. Specific EV-associated miRNAs, such as miR-21, miR-122, miR-224, and miR-221, show distinctive expression profiles in HCC and correlate with tumor stage, metastasis, and patient prognosis. Moreover, panels of circulating EV-associated miRNAs demonstrate superior diagnostic accuracy compared with traditional biomarkers, underscoring their potential as non-invasive tools for early detection and disease monitoring. Their inherent stability in biofluids and resistance to enzymatic degradation further support their application in liquid biopsy approaches. Despite promising results, continued research is essential to validate EV-associated miRNA signatures and to integrate these "silent messengers" into routine clinical practice for precision management of hepatocellular carcinoma. - Source: PubMed
Publication date: 2026/06/10
Caragut Roxana-LuizaMatei DanielaStefanescu HoriaAl Hajjar NadimSandru VasileBerindan-Neagoe IoanaCiocan Cristina AlexandraPop Laura AncutaSparchez Zeno - Lung cancer is a leading cause of cancer-related mortality worldwide, necessitating continued efforts to identify reliable biomarkers for improved detection and treatment strategies. Cisplatin has been approved for the treatment of lung cancer; however, its therapeutic efficacy is limited by drug resistance. Accordingly, previous studies have investigated microRNAs as potential predictors of drug resistance. - Source: PubMed
Publication date: 2026/06/10
Faridanjahromi FiroozehRezvani AlirezaJafarinia MojtabaYavarian Majid - Follicular thyroid carcinoma (FTC) makes up about 10% of all thyroid cancers and remains a diagnostic challenge due to its striking similarities to follicular thyroid adenoma (FTA). Both conditions share overlapping histopathological features, including vascular and capsular invasion, which complicates accurate diagnosis and often results in unnecessary surgical procedures. These interventions, while precautionary, can impose significant physical, emotional, and financial burdens on patients. As a result, identifying molecular biomarkers that can reliably differentiate between FTC and FTA is essential to improving diagnostic accuracy and optimizing patient care. MicroRNAs (miRNAs) have emerged as promising candidates for this purpose. These small, non-coding RNAs are key regulators of gene expression and are frequently dysregulated in cancer. In this study, we examined the expression of miR-221/222, miR-224, and miR-339 in formalin-fixed, paraffin-embedded (FFPE) tissue samples obtained from 48 patients, including 16 cases each of FTC, FTA, and multinodular goiter (MNG) as controls. Using quantitative real-time PCR (qRT-PCR), we found significant overexpression of miR-221/222 and miR-224 in FTC and FTA compared to MNG samples ( < 0.05). Although miR-339 expression was higher in FTC than in FTA, the difference was insignificant. Receiver operating characteristic (ROC) curve analysis demonstrated that these miRNAs have the potential to serve as reliable biomarkers, with strong sensitivity and specificity in distinguishing malignant from benign thyroid nodules. Our findings emphasize the role of miRNAs as powerful diagnostic tools that could transform the current approach to thyroid nodule management. By incorporating miRNA profiling into clinical workflows, it may be possible to reduce unnecessary surgeries, improve patient outcomes, and effectively tailor treatment strategies. To fully realize the potential of miRNAs in thyroid cancer diagnostics, further research involving larger sample sizes and diverse tissue types is needed. Such efforts could pave the way for their integration into routine clinical practice and open new avenues for targeted therapies. - Source: PubMed
Publication date: 2025/08/12
Mohammadi Kian MahnazLotfi JabarShabani NoushinTavangar Seyed MohammadHedayati MehdiSheikholeslami Sara